Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 5 , Pages 787-812 , October 2008

Osteoporosis in men

References 

  1. Boonen S, Kaufman JM, Goemaere S, et al. The diagnosis and treatment of skeletal osteoporosis: defining, assessing and preventing skeletal fragility in men. European Journal of Internal Medicine. 2007;18:6–17
  2. Seeman E. The structural basis of bone fragility in men. Bone. 1999;25:143–147
  3. Bergström U, Björnstig U, Stenlund H, et al. Fracture mechanisms and fracture pattern in men and women aged 50 years and older: a study of a 12-year population-based injury register, Umeå, Sweden. Osteoporosis International. 2008;19(9):1267–1273
  4. Lewis CE, Ewing SK, Taylor BC, et al. Predictors of non-spine fracture in elderly men: the MrOS study. Journal of Bone and Mineral Research. 2007;22:211–219
  5. Cawthon PM, Fullman RL, Marshall L, et al. Physical performance and risk of hip fractures in older men. Journal of Bone and Mineral Research. 2008;23:1037–1044
  6. Felsenberg D, Sülman AJ, Lunt M, et al. Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS). Journal of Bone and Mineral Research. 2002;17:716–724
  7. Cooper C, Atkinson EJ, O'Fallon NM, et al. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985–1989. Journal of Bone and Mineral Research. 1992;7:221–227
  8. De Laet CE, Van Hout BA, Burger H, et al. Hip fracture prediction in elderly men and women: validation in the Rotterdam study. Journal of Bone and Mineral Research. 1998;13:1587–1593
  9. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporosis International. 2006;17:1726–1733
  10. Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: on observational study. Lancet. 1999;353:878–882
  11. Forsen L, Sogaard AJ, Meyer HE, et al. Survival after hip fracture short- and long-term excess mortality according to age and gender. Osteoporosis International. 1999;10:73–78
  12. Poor W, Atkinson EJ, O'Fallon WM, et al. Determinants of reduced survival following hip fractures in men. Clinical Orthopaedics and Related Research. 1995;319:260–265
  13. Lips P, Cooper C, Agnusdei D, et al. Quality of life in patients with vertebral fractures: validation of the quality of life questionnaire of the European Foundation of Osteoporosis (QUALEFFO). Osteoporosis International. 1999;10:150–160
  14. Johanson C, Blanck D, Johnell O, et al. Bone mineral density is a predictor of survival. Calcified Tissue International. 1998;63:190–196
  15. Van Der Klift M, Pols HAP, Geleijnse JM, et al. Bone mineral density and morbidity in elderly men and women: the Rotterdam Study. Bone. 2002;30:634–648
  16. Kanis JA, On behalf of the World Health Organization Scientific Group . Assessment of osteoporosis at the primary health-care level. Technical report UK: World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield; 2007;
  17. Kiebzak CM, Beirnart GA, Perser K, et al. Undertreatment of osteoporosis in men with hip fracture. Archives of Internal Medicine. 2002;162:2217–2222
  18. Papaioannou A, Kennedy CC, Ionnadis G, et al. The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study. Osteoporosis International. 2008;19:581–587
  19. Van Staa TP, Dennison EM, Leufkens HG, et al. Epidemiology of fractures in England and Wales. Bone. 2001;29:517–522
  20. Kanis JA, Oden A, Johnell O, et al. The burden of osteoporotic fractures. A method for setting intercention tresholds. Osteoporosis International. 2001;12:417–427
  21. Kanis JA, Johnell O, Oden A, et al. Long-term risk of osteoporotic fractures in Malmo. Osteoporosis International. 2000;11:669–674
  22. Freitos SS, Barett-Connor E, Ensrud KE, et al. Rates and circumstances of clinical vertebral fractures in older men. Osteoporosis International. 2008;19(5):615–623
  23. O'Neill TW, Felsenberg D, Varlow J, et al. The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. Journal of Bone and Mineral Research. 1996;11:1010–1018
  24. Van Der Klift M, De Laet CEDH, McCloskey EV, et al. The incidence of vertebral fractures in men and women: the Rotterdam study. Journal of Bone and Mineral Research. 2002;17:1051–1056
  25. Ismail AA, O'Neil TW, Cooper C, et al. Mortality associated with vertebral deformity in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporosis International. 1998;8:291–297
  26. Hasserius R, Karlsson MK, Nilsson BE, et al. Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: a 10-year population-based study of 598 individuals from the Swedish Cohort in the European Vertebral Osteoporosis Study. Osteoporosis International. 2003;14:61–68
  27. Samelson EJ, Hannan MT, Zhang Y, et al. Incidence and risk factor for vertebral fracture in women and men: 25-year follow-up results from the population-based Framingham Study. Journal of Bone and Mineral Research. 2006;21:1207–1214
  28. Center JR, Bliuc D, Nguyen TV, et al. Risk of subsequent fracture after low-trauma fracture in men and women. JAMA: The Journal of the American Medical Association. 2007;297:387–394
  29. Johnell O, Kanis JA, Oden A, et al. Fracture risk following an osteoporotic fracture. Osteoporosis International. 2004;15:175–179
  30. Burger H, Van Daele PLA, Grashuis K, et al. Vertebral deformities and functional impairment in men and women. Journal of Bone and Mineral Research. 1997;12:152–157
  31. Pluijm SM, Tromp AM, Smit JH, et al. Consequences of vertebral deformities in older men and women. Journal of Bone and Mineral Research. 2000;15:1564–1572
  32. Matthis C, Weber U, O'Neill TW, et al. Health impact associated with vertebral deformities: results from the European Vertebral Osteoporosis Study (EVOS). Osteoporosis International. 1998;8:364–372
  33. Scana AC, Francis RM, Sutcliffe AM, et al. Case-control study of the pathogenesis and sequelae of symptomatic vertebral fracture in men. Osteoporosis International. 1999;9:91–97
  34. Cuddihy MT, Gabriel SE, Cowson CS, et al. Forearm fractures as predictors of subsequent osteoporotic fractures. Osteoporosis International. 1999;9:469–475
  35. Haentjes P, Johnell O, Kanis JA, et al. Evidence from data searches and life-table analysis for gender-related absolute risk of hip fracture after Colle's or spine fracture. Colle's fracture as an early and sensitive marker of skeletal fragility in white men. Journal of Bone and Mineral Research. 2004;19:1933–1944
  36. Nguyen ND, Ahlborg HG, Center JR, et al. Residual lifetime risk of fractures in women and men. Journal of Bone and Mineral Research. 2007;22:781–788
  37. Seeman E. The pathogenesis of bone fragility in women and men. Lancet. 2002;359:1841–1850
  38. Duan Y, Beck TJ, Wang XF, et al. Structural and biomechanical basis of sexual dimorphism in femoral neck fragility has its origins in growth and aging. Journal of Bone and Mineral Research. 2003;18:1766–1774
  39. Riggs BL, Melton LJ, Robb RA, et al. Population-based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites. Journal of Bone and Mineral Research. 2004;19:1945–1954
  40. Khosla S, Riggs BL, Atkinson EJ, et al. Effects of sex and age on bone microstructure at the ultradistal radius: a population-based non-invasive in vivo assessment. Journal of Bone and Mineral Research. 2006;21:124–131
  41. Aaron JE, Makins NB, Sagreiya K. The microanatomy of trabecular bone loss in normal aging men and women. Clinical Orthopaedics and Related Research. 1987;215:260–271
  42. Marshall LM, Lang TF, Lambert LC, et al. Dimensions and volumetric BMD of the proximal femur and their relation to age among older U.S. men. Journal of Bone and Mineral Research. 2006;21:1197–1206
  43. Riggs BL, Melton LJ, Robb RA, et al. A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men. Journal of Bone and Mineral Research. 2008;23:208–214
  44. Kaufman JM, Johnell O, Abadie E, et al. Background for studies on the treatment of male osteoporosis: state of the art. Annals of the Rheumatic Diseases. 2000;59:765–772
  45. Goemaere S, Van Pottelbergh I, Zmierczak H, et al. Inverse association between bone turnover rate and bone mineral density in community-dwelling men >70 years of age: no major role of sex steroid status. Bone. 2001;29:286–291
  46. Szulc P, Kaufman JM, Delmas PD. Biochemical assessment of bone turnover and bone fragility in men. Osteoporosis International. 2007;18:1451–1461
  47. Riggs BL, Khosla S, Melton LJ. Sex steroids and the construction and conservation of the adult skeleton. Endocrine Reviews. 2002;23:279–302
  48. Gennari L, Nuti R, Bilezikian JP. Aromatase activity and bone homeostasis in men. The Journal of Clinical Endocrinology and Metabolism. 2004;89:5898–5907
  49. Vanderschueren D, Vandenput L, Boonen S, et al. Androgens and bone. Endocrine Reviews. 2004;25:389–425
  50. Bouillon R, Bex M, Vanderschueren D, et al. Estrogens are essential for male pubertal periosteal bone expansion. The Journal of Clinical Endocrinology and Metabolism. 2004;89:6025–6029
  51. Vanderschueren D, Venken K, Ophoff J, et al. Clinical review: Sex steroids and the periosteum – Reconsidering the roles of androgens and estrogens in periosteal expansion. The Journal of Clinical Endocrinology and Metabolism. 2006;91:378–382
  52. Lorentzon M, Swanson C, Andersson N, et al. Free testosterone is a positive, whereas estradiol is a negative, predictor of cortical bone size in young Swedish men: the GOOD Study. Journal of Bone and Mineral Research. 2005;20:1334–1341
  53. Stepan JJ, Lachman M, Zverina J, et al. Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. The Journal of Clinical Endocrinology and Metabolism. 1989;69:523–527
  54. Stoch SA, Parker RA, Chen LP, et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. The Journal of Clinical Endocrinology and Metabolism. 2001;86:2787–2791
  55. Mittan D, Lee S, Miller E, et al. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. The Journal of Clinical Endocrinology and Metabolism. 2002;87:3656–3661
  56. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocrine Reviews. 2005;26:833–836
  57. Khosla S, Melton LJ, Robb RA, et al. Relationship of volumetric BMD and strucural parameters at different skeletal sites to sex steroid levels in men. Journal of Bone and Mineral Research. 2005;20:730–740
  58. Khosla S, Melton LJ, Achenbach SJ, et al. Hormonal and biochemical determinants of trabecular microstructure at the ultradistal radius in women and men. The Journal of Clinical Endocrinology and Metabolism. 2006;91:885–891
  59. Szulc P, Munoz F, Clawstra t B, et al. Bioavailable estradiol may be an important determinant of osteoporosis in men: the MINOS Study. The Journal of Clinical Endocrinology and Metabolism. 2001;86:192–199
  60. Genmari L, Merlotti D, Martini G, et al. Longitudinal association between sex hormone levels, bone loss and bone turnover in elderly men. The Journal of Clinical Endocrinology and Metabolism. 2003;88:5327–5333
  61. Szulc P, Hofbauer LC, Heufelder AE, et al. Osteoprotegerin serum levels in men: correlation with age, estrogen and testosteron status. The Journal of Clinical Endocrinology and Metabolism. 2001;86:3162–3165
  62. Falahati-Nini A, Riggs BL, Atkinson EJ, et al. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. The Journal of Clinical Investigation. 2000;106:1553–1560
  63. Sanyol A, Hoey KA, Mödderer VI, et al. Regulation of bone turnover by sex steroids in men. Journal of Bone and Mineral Research. 2008;23:705–714
  64. Khosla S, Melton LJ, Atkinson EJ, et al. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. The Journal of Clinical Endocrinology and Metabolism. 2001;86:3555–3561
  65. Van Pottelbergh I, Goemaere S, Kaufman JM. Bioavailable estradiol and an aromatase gene polymorphism are determinants of bone mineral density changes in men over 70 years of age. The Journal of Clinical Endocrinology and Metabolism. 2003;88:3075–3081
  66. Gennari L, Masi L, Merlotti D, et al. A polymorphic CYP 19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolism. The Journal of Clinical Endocrinology and Metabolism. 2004;89:2803–2810
  67. Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors and the skeleton. Endocrine Reviews. 2008;29:535–559
  68. Kaufman JM, Taelman P, Vermeulen A, et al. Bone mineral status in growth hormone-deficient male with isolated and multiple pituitary deficiencies of childhood onset. The Journal of Clinical Endocrinology and Metabolism. 1992;74:118–123
  69. Szulc P, Muno ZF, Marchand F, et al. Role of vitamine D and parathyroïd hormone in the regulation of bone turnover and bone mass in men: the MINOS Study. Calcified Tissue International. 2003;73:520–530
  70. O'Neill TW, Lunt M, Silman AJ, et al. The relationship between bone density and incident vertebral fracture in men and women. Journal of Bone and Mineral Research. 2002;17:2214–2221
  71. Cummings SR, Cawthon PM, Ensrud KE, et al. BMD and risk of hip and nonvertebral fractures in older men: a prospective study and comparison wih older women. Journal of Bone and Mineral Research. 2006;21:1550–1556
  72. Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. Journal of Bone and Mineral Research. 2005;20:1185–1194
  73. Canalis E, Mazziotti G, Giustina A, et al. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporosis International. 2007;18:1319–1328
  74. Macadams MR, White RH, Chipps BE. Reduction of serum testosterone levels during chronic glucocorticoïd therapy. Annals of Internal Medicine. 1986;104:648–651
  75. Kamischke A, Kemper DE, Castel MA, et al. Testosterone levels in men with chronic obstructive pulmonary disease with and without glucocorticoid therapy. The European Respiratory Journal. 1998;11:41–45
  76. Biskobing DM. COPD and osteoporosis. Chest. 2002;121:603–620
  77. Cohen A, Shane E. Osteoporosis after solid organ and bone marrow transplantation. Osteoporosis International. 2003;14:617–630
  78. Kanis JA, Johansson H, Johnell O, et al. Alcohol intake as a risk factor for fracture. Osteoporosis International. 2005;16:737–742
  79. Bilezikian JP. Osteoporosis in men. The Journal of Clinical Endocrinology and Metabolism. 1999;84:3431–3434
  80. Van Pottelbergh I, Goemaere S, Zmierczak H, et al. Deficient acquisition of bone during maturation underlies idiopathic osteoporosis in men. Journal of Bone and Mineral Research. 2003;18:303–311
  81. Legrand E, Chappard D, Pascaretti C, et al. Trabecular bone microarchitecture, bone mineral density and vertebral fractures in male osteoporosis. Journal of Bone and Mineral Research. 2000;15:13–19
  82. Cohen-Solal ME, Baudouin C, Omouri M, et al. Bone mass in middle-aged osteoporotic men and their relatives: familial effect. Journal of Bone and Mineral Research. 1998;13:1909–1914
  83. Pelat C, Van Pottelbergh I, Cohen-Solal M, et al. Complex segregation analysis accounting for GxE of bone mineral density in European pedigrees selected through a male proband with low BMD. Annals of Human Genetics. 2007;71:29–42
  84. Kaufman JM, Ostertag A, Saint-Pierre A, et al. Genome-wide linkage screen of bone mineral density (BMD) in European pedrigrees ascertained through a male relative with low BMD values: evidence for quantitative trait loci on 17q21-23, 11q12–13, 13q12-14 and 22q11. The Journal of Clinical Endocrinology and Metabolism. 2008, July 29;[Epub ahead of print]
  85. Van Pottelbergh I, Goemaere S, Zmierczak H, et al. Perturbed sex steroid status in men with idiopathic osteoporosis and their sons. The Journal of Clinical Endocrinology and Metabolism. 2004;89:4949–4953
  86. Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004;35:375–382
  87. Kanis JA, Johansson H, Odem A, et al. A family history of fracture and fracture risk: a meta-analysis. Bone. 2004;35:1029–1037
  88. De Laet C, Kanis JA, Oden A, et al. Body mass index as predictor of fracture risk: a meta-analysis. Osteoporosis International. 2005;16:1330–1338
  89. Kanis JA, Johnell O, Oden A, et al. Smoking and fracture: a meta-analysis. Osteoporosis International. 2005;16:155–162
  90. Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. Journal of Bone and Mineral Research. 2004;19:893–899
  91. Schuit SCE, van der Klift M, Weel AEAM, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam study. Bone. 2004;34:195–202
  92. Szulc P, Munoz F, Duboeuf , et al. Bone mineral density predicts osteoporotic fractures in elderly men: the MINOS study. Osteoporosis International. 2005;16:1184–1192
  93. Khosla S, Amin S, Orwoll E. Osteoporosis in men. Endocrine Reviews. 2008;29:441–464
  94. Devogelaer JP, Goemaere S, Boonen S, et al. Evidenced-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporosis International. 2006;17:8–19
  95. Body JJ, Bergmann P, Boonen S, et al. Management of cancer treatment-induced bone loss in early breast and prosate cancer: a consensus paper of the Belgian Bone Club. Osteoporosis International. 2007;18:1439–1450
  96. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. The New England Journal of Medicine. 2000;343:604–610
  97. Boonen S, Orwoll S, Wendeworth D, et al. Risedronate is effective in men with osteoporosis regardless of baseline testosterone levels and prevalent fracture status. Journal of Bone and Mineral Research. 2006;21(suppl 1):S110–S110
  98. Ringe JD, Faber H, Farahmad P, et al. Efficacy of residronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatology International. 2006;26:427–431
  99. Sato Y, Iwamoto J, Kanoko T, et al. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Archives of Internal Medicine. 2005;165:1743–1748
  100. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. The New England Journal of Medicine. 2007;357:1799–1809
  101. Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. The Journal of Urology. 2003;169:2008–2012
  102. Michaelson MD, Kaufman DS, Lee H, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. Journal of Clinical Oncology. 2007;25:1038–1042
  103. Orwoll E, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. Journal of Bone and Mineral Research. 2003;18:9–17
  104. Kaufman J-M, Orwoll E, Goemaere S, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporosis International. 2005;16:510–516
  105. Reginster JY, Felsenberg D, Boonen S, et al. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: results of a five-year, randomized, placebo-controlled trial. Arthritis and Rheumatism. 2008;58:1687–1695

PII: S1521-690X(08)00099-7

doi: 10.1016/j.beem.2008.09.005

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 5 , Pages 787-812 , October 2008

Article Tools